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 Sir, 
relapsing polychondritis (RPC) is an immune-mediated condition associated with 
inflammation in cartilaginous structures and other tissues throughout the body, particularly 
the ears, nose, eyes, joints, and respiratory tract. Approximately one-third of RPC cases 
occur in association with other diseases, such as systemic vasculitis, connective tissue 
disorders, or myelodysplastic syndromes. 
We report the case of a 73-year-old man with antiphospholipid syndrome (APS) 
associated with relapsing polychondritis. 
He came to our attention with a history of ultrasound-proven, recurrent thrombophlebitis 
(since 2009, two episodes involving popliteal veins, one involving the cephalic vein).   
Coagulation screening was performed and lupus anticoagulant (LA) resulted positive 
(testing was repeated 16 weeks later;  testing to confirm  lupus anticoagulant positivity was 
performed  1  week after discontinuing vitamin K antagonists,  when the international 
normalized ratio was less than 1.5. Bridging therapy after vitamin K antagonist 
discontinuation to low-molecular-weight heparin was  carried out). LA measurement 
included three tests: dilute Russell’s viper venom time (dRVVT, Hemosil, LA-
screen/confirm, Instrumentation Laboratory, Lexington,USA), partial thromboplastin time-
LA (PTT-LA, Diagnostica Stago, Asnieres,France), silica clotting time (SCT, HemosIL™, 
DiaPharma Group, Inc. Ohio, USA). If PTT-LA was prolonged, the hexagonal phospholipid 
neutralization test was performed as confirmation (STACLOT-LA, Diagnostica STAGO, 
Asnières,France).  
Anticardiolipin antibodies (ELISA kit, Phadia, EliA Cardiolipin IgG/IgM) and anti ß 2-
glycoprotein I antibody (ELISA kit, Phadia, EliA ß2 Gliocoprotein I IgG/IgM were searched 
for twice 16 weeks apart and resulted negative. 
Thus, a diagnosis of Antiphospholipid Syndrome was made according to Myakis et al. (1) ,  
and long term anticoagulation therapy was started.  
During follow up the patient presented with persistent fever (up to 38.5 °C),    bilateral 
external ear inflammation, nasal involvement with crusting and cartilage flogosis and 
diffuse polyarthralgia.  During the same time period, he was taken to the Emergency Room 
with ocular inflammation and he was discharged with a diagnosis of scleritis/episcleritis 
that was successfully treated with steroids. His laboratory findings revealed elevated 
erythrocyte sedimentation rate (up to 100 mm/h) and high C-reactive protein levels (12.1 
mg/dl).  ANA, ENA and ANCA were negative. Blood tests revealed normocytic and 
normochromic anaemia (Hb 10.2 g/dl), which is  consistent with anaemia occurring  in 
chronic diseases. Considering  the patient's age and the ongoing anticoagulation therapy, 
bone marrow biopsy to rule out  myelodysplastic syndromes was postponed and 
haematologic  follow up was planned. 
Due to the presence of bilateral auricular chondritis, non-erosive, sero-negative 
inflammatory polyarthritis, nasal chondritis and ocular inflammation (scleritis/episcleritis),  a 
diagnosis of RPC was made on the basis of McAdam's criteria (2). Positive histology of the 
involved cartilage was not required for inclusion, since the clinical setting itself was 
diagnostic for RPC (3). Therapy with 10 mg/daily prednisone was started, leading to  
immediate improvement of the auricular lesions and a rapid decrease of the 
sign/symptoms of inflammation. During  15 months of follow-up we observed no  
recurrences  with a maintenance dose of 5 mg/daily prednisone. 
Some studies have speculated on the possible association between antiphospholipid 
antibodies and RPC. However, no convincing evidence regarding the possible association 
between RPC and APS has been found (3).  When APS occurs in RPC it seems to be 
more closely related to associated conditions like  Systemic Lupus Erythematosus. (4) 
In our case, no signs or symptoms (except arthralgia) were suggestive of  Lupus-like 
conditions,  and RPC occurred in a pre-existing condition of Primary APS. 
To date, the co-existence of APS and RPC has not been convincingly reported in English 
language scientific literature. The present case supports the possible association between 
these two rare conditions. 
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